WallStreetZenWallStreetZen

NASDAQ: LAB
Standard Biotools Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their LAB stock forecasts and price targets.

Forecast return on equity

Is LAB forecast to generate an efficient return?

Company
-17.1%
Industry
10.72%
Market
-20.75%
LAB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is LAB forecast to generate an efficient return on assets?

Company
-13.03%
Industry
10.63%
LAB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LAB earnings per share forecast

What is LAB's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.22
Avg 2 year Forecast
-$0.19

LAB revenue forecast

What is LAB's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$80.7M-47.68%
Avg 2 year Forecast
$78.7M-48.98%
LAB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LAB revenue growth forecast

How is LAB forecast to perform vs Diagnostics & Research companies and vs the US market?

Company
-47.68%
Industry
2.68%
Market
126.66%
LAB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LAB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LAB vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
LAB$1.26N/AN/A
PSNL$4.89$7.83+60.18%Buy
MYGN$6.37$8.14+27.83%Buy
FLGT$22.17$25.33+14.27%Buy
CSTL$24.01$37.25+55.14%Strong Buy
View Top Diagnostic & Research Stocks

Standard Biotools Stock Forecast FAQ

What is LAB's earnings growth forecast for 2025-2026?

(NASDAQ: LAB) Standard Biotools's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 36.86%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 55.04%.

Standard Biotools's earnings in 2025 is -$120,502,000.On average, 1 Wall Street analyst forecast LAB's earnings for 2025 to be -$84,038,922, with the lowest LAB earnings forecast at -$84,038,922, and the highest LAB earnings forecast at -$84,038,922.

In 2026, LAB is forecast to generate -$72,579,069 in earnings, with the lowest earnings forecast at -$72,579,069 and the highest earnings forecast at -$72,579,069.

If you're new to stock investing, here's how to buy Standard Biotools stock.

What is LAB's revenue growth forecast for 2025-2026?

(NASDAQ: LAB) Standard Biotools's forecast annual revenue growth rate of -47.68% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 2.68%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 126.66%.

Standard Biotools's revenue in 2025 is $154,244,000.On average, 1 Wall Street analysts forecast LAB's revenue for 2025 to be $30,827,004,731, with the lowest LAB revenue forecast at $30,827,004,731, and the highest LAB revenue forecast at $30,827,004,731.

In 2026, LAB is forecast to generate $30,063,014,527 in revenue, with the lowest revenue forecast at $30,063,014,527 and the highest revenue forecast at $30,063,014,527.

What is LAB's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: LAB) forecast ROA is -13.03%, which is lower than the forecast US Diagnostics & Research industry average of 10.63%.

What is LAB's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: LAB) Standard Biotools's current Earnings Per Share (EPS) is -$0.31. On average, analysts forecast that LAB's EPS will be -$0.22 for 2025, with the lowest EPS forecast at -$0.22, and the highest EPS forecast at -$0.22. In 2026, LAB's EPS is forecast to hit -$0.19 (min: -$0.19, max: -$0.19).

What is LAB's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: LAB) forecast ROE is -17.1%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.